Document 0646
 DOCN  M9490646
 TI    Biology of disease and clinical aspects of AIDS-associated lymphoma: a
       review.
 DT    9411
 AU    Stein ME; Spencer D; Dansey R; Bezwoda WR; Northern Israel Oncology
       Centre, Haifa.
 SO    East Afr Med J. 1994 Apr;71(4):219-22. Unique Identifier : AIDSLINE
       MED/94341200
 AB    AIDS-related lymphoma was not apparent until 1985, when a statistically
       significant increase in the frequency of lymphoma had occurred. Over 50%
       are high-grade lymphoma, either immunoblastic or small, noncleaved cells
       (Burkitt's-like lymphoma), with involvement of extranodal sites such as
       the central nervous system (> one-third of patients), gastrointestinal
       tract, skin and bone marrow. Optimal therapy for AIDS-associated
       lymphoma has not yet been defined. Using intensive chemotherapy
       protocols, high response rates, albeit of brief duration, have been
       demonstrated. The majority of patients succumbed to intercurrent
       opportunistic infections. Poor prognosis has been particularly noted in
       debilitated patients, patients with a CD4 cell count of < 200/dl, bone
       marrow and brain involvement and a history of AIDS before diagnosing the
       lymphoma. New strategies in the management of patients with
       AIDS-lymphoma should include cytotoxic therapy, antiretroviral therapy,
       anti-pneumocystic Carini pneumonia, prophylaxis of CNS spread and marrow
       protective therapy (haematopoietic growth factors).
 DE    Antineoplastic Agents/THERAPEUTIC USE  Antiviral Agents/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/*ETIOLOGY/MORTALITY  Cause of
       Death  Drug Therapy, Combination  Human  *HIV-1  *Lymphoma,
       AIDS-Related/BLOOD/DIAGNOSIS/EPIDEMIOLOGY/ETIOLOGY/  THERAPY  Prognosis
       Risk Factors  Survival Rate  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).